Rationale: Apoptosis and fatty acid-binding protein-4 (FABP4) induced-endoplasmic reticulum (ER) stress in macrophage is an important pathological process in several vascular occlusive diseases, including atherosclerosis, both of which are accelerated by lipids or inflammatory cytokines.
In September 2012, the average time from submission to first decision for all original research papers submitted to Circulation Research was 11.5 days. 
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INTRODUCTION
Atherosclerosis, a lipid-driven, chronic inflammatory disease of large and medium-sized arteries, is the pathological basis for multiple cardiovascular diseases, a leading cause of mortality worldwide. 1 Many kinds of immune cells, such as macrophages and CD4 + T cells contribute to formation and advance of lesions. [2] [3] [4] Recently, Th17 cells producing IL-17A were found involved in the pathogenesis of atherosclerosis. [5] [6] [7] [8] Although not unanimous, [9] [10] [11] increasing evidence, including our own studies, suggests that IL-17A is pro-atherogenic. [12] [13] [14] Increased IL-17A expression and number of IL-17A + T cells were detected in human 15 or murine atherosclerotic lesions and found associated with plaque size. 16, 17 Furthermore, atherosclerotic lesions were reduced with knockout of IL-17A 18, 19 or blockade of IL-17A protein with specific neutralizing antibody 17, 20 or adenovirus-produced IL-17A
receptor, 21 whereas treatment with exogenous IL-17A aggravated the formation of lesions in ApoE-/-mice. 17 In addition, data from humans and a mouse model suggested that IL-17A enhances the vulnerability of plaque. 12, 15, 11 However, the mechanism by which IL-17A accelerates the formation and progression of atherosclerosis remains poorly understood.
Endoplasmic reticulum (ER) is site where newly synthesized secretory and membrane-associated proteins are correctly folded and assembled. 22, 23 Once the ER function is perturbed by various pathological conditions, newly synthesized unfolded proteins accumulate in the ER, which results in ER stress, also defined as the unfolded protein response (UPR). 24, 25 The initiation of canonical UPR engages 3 distinct signaling branches mediated by protein kinase R (PKR)-like eukaryotic initiation factor 2 kinase (PERK), inositol-requiring enzyme 1 (IRE1) 26, 27 and activating transcription factor 6 (ATF6). 28 PERK, by phosphorylating eukaryotic translation initiation factor 2 (eIF2 ), IRE1 and ATF6, by promoting the expression of their downstream targets such as transcription factor genetic X-box binding protein 1 (XBP-1), [29] [30] [31] inhibits protein translation, stimulation of protein degradation, and production of chaperone proteins. 22, 23 The recovery of ER function by the UPR is critical for cell survival, but chronic or unresolved ER stress can lead to apoptosis. 32 Accumulating evidence indicates that the UPR is chronically activated in macrophages and endothelial cells in atherosclerotic lesions. Oxidative stress, high levels of intracellular cholesterol and saturated fatty acids in advanced lesions can lead to prolonged activation of the UPR. 33 Prolonged ER stress further triggers macrophage apoptosis by up-regulating expression of C/EBP-homologous protein (CHOP) or caspase12, [34] [35] [36] [37] which in turn leads to plaque necrosis and the progression of atherosclerosis if the apoptotic cells are not rapidly cleared. 38 However, improvement of the ER with IL-17A antibody reduced apoptosis in atherosclerotic plaques. 20 We recently showed that IL-17A promotes apoptosis of human vascular endothelial cells by a mitochondrial pathway in vitro. 40 Macrophages, a key player in atherosclerosis formation, are targets of IL-17A and participate in IL-17A-mediated inflammation. 41 So we make a hypothesis that IL-17A may activate an ER stress pathway, thereby altering the function and survival of macrophages and the course of atherogenesis.
Fatty acid-binding protein-4 (FABP-4) (aP2) is expressed specifically in both adipocytes and macrophages and is a cytosolic lipid chaperone that regulates cellular lipid metabolism and reception of lipid signals.
42 aP2 promotes chronic metabolic diseases, including atherosclerosis. aP2 deficiency in macrophages protects against atherosclerosis. [43] [44] [45] It is the predominant regulator of lipid-induced macrophage ER stress in vitro and in vivo. 39 However, whether IL-17A can affect aP2 expression in macrophages to regulate ER stress is unknown.
In this study, we found that IL-17A induced ER stress in macrophages through aP2. Prolongation of IL-17A-induced ER stress promoted the apoptosis of macrophages and atherosclerosis. We established a previously unrecognized link between IL-17A and ER stress through cytosolic lipid chaperone aP2 in macrophages and provide a new insight for understanding the role of IL-17A in atherosclerosis
METHODS
Animals.
Male C57BL/6 wild-mice and ApoE-/-mice were purchased from Beijing University. Mice were 6-8 weeks old (21-25g) and were housed at a constant temperature (24 ) , under a 12-h dark/12-h light cycle room in the Animal Care Facility of Shandong University Medical School according to institutional guidelines. All animal studies were approved by the Animal Care and Utilization Committee of Shandong University, China.
In vivo application of exogenous IL-17A, 4-phenyl butyric acid (PBA) and ap2 inhibitor. ApoE-/-mice (n=10 for each group) were fed a high-cholesterol diet from 8 weeks of age. Four weeks later, two groups for treatment once a week for 5 weeks: intraperitoneal injection with exogenous recombinant IL-17A, 0.02% of recombinant mouse IL-17A in normal saline (2 g/mouse/time, PMC0175, Invitrogen, Clasbad, CA, USA); and normal saline containing 0.02% albumin as a control 9, 17 . The third group (n=10) , mice were pretreated before IL-17A with the chemical chaperone PBA (P21005, Sigma-Aldrich, St. Louis, MO, USA) (100 mg/kg/time) twice a week for 5 weeks, 39 at the same time mice also received IL-17A treatment (2 g/mouse/time) once a week for 5 weeks. The fourth group (n=7) fed with a high-cholesterol diet from 8 weeks of age and two weeks later, mice were treated by oral gavage with vehicle including 10% 1-methyl-2-pyrrolidone and 5% cremophor EL with ethanol in 100 l of water or 20mg/kg/d of the aP2 inhibitor BMS309403 dissolved in the vehicle for 6 weeks 39, 45 . Mice also received IL-17A treatment (2 g/mouse/time) once a week for 5 weeks after four weeks high-cholesterol diet. . The . Th (P2 (P Induction and culture of human monocyte-derived macrophages and THP-1-derived macrophages. Peripheral blood mononuclear cells (PBMCs) from healthy volunteer blood at Shandong University Medical School were isolated by Ficoll density gradient centrifugation and washed twice with serum-free RPMI 1640 medium (Gibco, Invitrogen, Clasbad, CA, USA). PBMCs were then plated at 3 ml/well in 6-well cell culture plates, 3 hours later un-adherent cells were removed and adherent cells cultured with RPMI 1640 complete medium (10% FBS, 1% L-glutamine, 1% sodium pyruvate, 1% non-essential amino acids, 1% penicillin/streptomycin and 50ng/ml rhGM-CSF) (catalog: 300-03, PeproTech, Suzhou, JS, P.R. China). Half of the medium was replaced every 2 days for culture for 7 days. 46 On the day of the experiment, the cells were washed 3 times in warm PBS and incubated as described in the figure legends. THP-1 cell lines were cultivated in 6-well flat-bottom plates with DMEM supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomyin and PMA(50ng/ml) for 48 hours, then the cells were washed 3 times in warm PBS and incubated as described in the figure legends. 
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IL-17A promotes macrophage apoptosis in vitro.
Accumulated evidence indicates that Th17 cells and its major effector, IL-17A, play a pro-atherogenic role. However, the underlining mechanism is unclear. Nowadays, there is increasing evidence in vitro and in vivo indicating that late apoptosis of intimal cells, notably macrophages, plays an important role in atherosclerotic plaque progression. 49 To study the mechanism by which IL-17A promotes the development of atherosclerosis, we firstly examined the effect of IL-17A on apoptosis of macrophages. We showed that macrophages treated by IL-17A (25ng/ml, 50ng/ml and 100ng/ml) for 48 hours exhibited increase in apoptotic bodies as white arrows point and the number of cells containing apoptotic bodies further arose at 72 hours ( Figure.1A) . Next, we confirmed the role of IL-17A promoting macrophages apoptosis by flow cytometry. As shown in Figure 1B , C, the number of late apoptotic (Annexin V+ PI+) macrophages increased markedly when cells were treated in IL-17A 25ng/ml for 48 hours and 72 hours. Furthermore, the effect of IL-17A on macrophage was in a dose dependent manner. In addition, we also observed whether IL-17A accelerated ox-LDL induced apoptosis in macrophages. Results from flow cytometry analysis showed that the percentage of PI positive cells was significant higher with ox-LDL and IL-17A stimulation (Supp Figure I ). This indicates that prolonged-IL-17A intervention raised significantly macrophage apoptosis and promoted ox-LDL-induced macrophage apoptosis or necrocytosis in vitro. 
IL-17A induced ER stress in murine and human macrophages in vitro.
Our previous report demonstrated that IL-17A induced vascular endothelial cell apoptosis. 40 Here we found that IL-17A also promoted macrophage apoptosis. Because ER stress is an important mechanism of macrophage apoptosis, we further investigated the impact of IL-17A on ER stress in murine and human macrophages. IL-17A time-dependently increased levels of phosphorylated PERK (p-PERK) and its downstream molecule p-eIF2 in the murine macrophage cell line (RAW264.7) and primary peritoneal macrophages ( 
Exogenous IL-17A induced ER stress in macrophages in atherosclerotic lesions of ApoE-/-mice.
To confirm the impact of IL-17A on ER stress in vivo, we treated ApoE-/-mice that had been fed with high cholesterol diet with recombinant IL-17A and analyzed the expression of the ER stress markers p-PERK, p-eIF2 and XBP-1s in the arterial wall with plaque and in local lesions. Western blot analysis revealed significantly up-regulated levels of p-PERK, p-eIF2 and XBP-1s with IL-17A treatment ( Figure 3A ,B) and immunohistochemistry revealed increased levels of p-eIF2 (20.59% ±1.35% v.s. 30.75%±3.04%, P<0.05)and p-PERK (28.59% ±1.36% v.s. 38.55% ±1.80%, P<0.01) (n=5) mainly in macrophage-dense areas of atherosclerotic lesions ( Figure 3C ). Of note, IL-17A had no effect on blood lipid levels or body weight (Supp. Table I), which indicates that IL-17A directly induced ER stress responses in macrophages in vivo without affecting lipid metabolism.
Inhibiting ER stress alleviated IL-17A-induced ER stress and reversed IL-17A-aggravated atherogenesis in ApoE-/-mice.
4-phenyl butyric acid (PBA), a chemical chaperone that can mimic endogenous chaperone Bip and alleviate ER stress, provides an experimental opportunity to investigate the role of ER stress in diseases. 39, 50 Previous research has indicated that PBA treatment could reduce the atherosclerosis in ApoE-/-mice with high fat diet. 39 In our early experiment, this result had substantially been reproduced (Supp. Figure II) . To clarify the cause of ER stress in IL-17A-aggravated atherogenesis, we treated ApoE-/-mice with recombinant mouse IL-17A (2 g) or IL-17A with PBA (100mg/kg). IL-17A and/or PBA had no significant impact on body weight or blood lipid profiles of mice (Supp .  Table I ). However, PBA could markedly block IL-17A-induced ER stress responses: levels of p-PERK, p-eIF2 and XBP-1s protein in vessels with atherosclerotic plaque were lower with PBA than with IL-17A alone (n=5) ( Figure 3A ,B To clarify whether blockade of IL-17A-induced ER stress by PBA could reverse IL-17A-aggravated atherogenesis in ApoE-/-mice, we analyzed plaque area in aortic root sections of atherosclerotic mice. Plaque size was lower by 45% with PBA treatment than with IL-17A alone (P<0.001) ( Figure 3D ), along with suppression of IL-17A-induced ER stress. These data establish a link between ER stress and IL-17A-accelarated atherosclerotic lesions.
IL-17A-induced ER stress leads to apoptosis of macrophages.
ER-associated CHOP and caspase 12 pathways are involved in ER stress-mediated apoptosis. [34] [35] [36] [37] To elucidate the association of IL-17A-induced ER stress and macrophage apoptosis, we examined the expression of CHOP and caspase 12 in murine macrophages in vitro. The expression of CHOP was markedly increased ( Figure 4A ) but that of caspase 12 only slightly up-regulated with IL-17A treatment (data not shown). The expression of cleaved caspase 3 was also increased ( Figure  4A ), which suggests that IL-17A probably led to macrophage apoptosis by activating the CHOP-caspase 3 axis.
To address this issue in vivo, we examined the expression of CHOP, caspase 12 and caspase 3 in aortic vasculature with atherosclerotic lesions. The protein expression of CHOP and cleaved caspase 3 was markedly higher with IL-17A than control treatment by western blot ( To investigate whether the IL-17A-induced macrophage apoptosis was attributed to ER stress signal pathways, we examined the levels of CHOP and caspase 3 and apoptotic cells with PBA treatment. The expression of CHOP and caspase 3 and number of apoptotic cells was lower with PBA than with IL-17A alone ( Figure 4B ,C,D), which indicates that IL-17A induces apoptosis in macrophages through the ER stress in mice and probably mainly through activating CHOP-caspase3 pathway, which may accelerate the progression of atherosclerosis.
aP2 is required for IL-17A-induced ER stress in macrophages.
Recent study has suggested that aP2, an intracellular "lipid chaperone", mediates saturated fatty acid-induced ER stress and apoptosis in macrophages. 39, 51 Therefore, aP2 might be involved in IL-17A-induced ER stress in macrophages. We first investigated the effect of IL-17A on aP2 expression in macrophages. IL-17A up-regulated aP2 mRNA and protein levels in macrophages in vitro ( Figure 5A ) and significantly increased the expression of aP2 in atherosclerotic lesions in vivo (Control v.s. IL-17A-treated: 15.03% ± 1.3% versus 23.65% ± 2.11%, P<0.01, n=5) ( Figure 5B ). To determine the role of increased aP2 level in IL-17A-induced ER stress, we treated macrophages with the aP2 inhibitor (BMS309403) and IL-17A and found that 50 M BMS309403 almost completely inhibited the expression of aP2 (Supp. Figure III) . 45 Importantly, inhibition of aP2 markedly reduced Figure 5C ). Therefore, aP2 expression is required at least in part for IL-17A-induced ER stress in macrophages.
To address this issue in vivo, we treated ApoE-/-mice with recombinant mouse IL-17A (2 g) or IL-17A with aP2 inhibitor (BMS309403)(20mg/kg/d) 39, 45 . IL-17A and/or aP2 inhibitor had no significant impact on body weight or blood lipid profiles of mice (Supp . Table II) . However, inhibition of aP2 could markedly block IL-17A-induced ER stress in macrophage.As shown in Figure  5D ,5E, levels of p-PERK, p-eIF2 and XBP-1s protein in vessels with atherosclerotic plaque were lower with aP2 inhibitor than with IL-17A alone by Western Western blot or by Immunohistochemistry staining (n=7) (p-PERK: 38.55% ±1.80% v.s. 16.66% ±1.23%, P<0.001; p-eIF2 30.75% ± 3.04% v.s. 17.59% ± 1.10%, P<0.01, n=5; Figure 5E ), with no significant reduction in proportion of macrophage to lesion area. So, aP2 inhibitor also reduced IL-17A-induced macrophage ER stress in vivo.
To clarify whether blockade of IL-17A-induced ER stress by aP2 inhibitor could reverse IL-17A-aggravated apoptotic macrophages and atherogenesis in ApoE-/-mice, we analyzed the level of CHOP proteins, numbers of apoptotic macrophage and plaque area in aortic root sections of atherosclerotic mice. The expression of CHOP and number of apoptotic cells was lower with aP2 inhibitor than with IL-17A alone ( Figure 5D ,5E), which indicates that IL-17A induces apoptosis in macrophages through the ER stress in mice could be reversed by aP2 inhibitor. And, plaque size in aortic root ( Figure 5F , p<0.05, n=5) and on aortic arch-thoracic-abdominal aorta ( Figure 5G , p<0.05, n=3) was lower with aP2 inhibitor treatment than with IL-17A alone, along with suppression of IL-17A-induced ER stress. These data suggest that IL-17A induced ER stress in macrophage through up-regulating the expression of aP2.
IL-17A up-regulated aP2 by activating NF-B and extracellular signal-regulated kinase (ERK)/p38 mitogen-activated protein kinase (MAPK) pathways.
Next, we investigated the underlying molecular mechanisms of IL-17A-mediated aP2 upregulation. IL-17A induced the phosphorylation of I B (p-I B) in macrophages within 15 min ( Figure 6A ) and up-regulated the expression of p-ERK at 15 min, then p-p38 MAPK at 2 h, wherease p-Jun N-terminal kinase (p-JNK) was activated later, at 3 h after IL-17A stimulation ( Figure 6B ). These data indicate that IL-17A could activate NF-B and MAPK signal pathways in macrophages in vitro.
To determine the cause of these signal pathways in IL-17A-upregulated aP2 level, we treated mouse macrophages with the inhibitor of NF-B (PDTC), ERK (PD98059), JNK (SP600125) or p38 (SB203580) for 3, 6, and 9 h. Western blot analysis revealed that inhibition of NF-B, ERK and p38 but not JNK suppressed the expression of aP2 ( Figure 6D ). Thus, IL-17A up-regulates the expression of aP2 by activating NF-B and ERK, p38 MAPK signaling pathway in macrophages. 
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Today, the role of IL-17A in atherosclerosis development still remains controversial. Some research have proposed that IL-17A plays an atheroprotective role, 9 ,52 while others have demonstrated IL-17A does an proatherogeitic role. 14, 17, 18, 20 In addition, a few of reports have showed that the deficiency of IL-17A or IL-17A blockage by mouse-anti-mouse IL-17A have no effect on plaque burden. 10, 11 Here, we indicate that IL-17A can induce ER stress in both murine and human-derived macrophages in vitro, and in the atherosclerotic lesions of ApoE-/-mice which contribute to IL-17A-caused macrophage apoptosis and aggravation of atherogenesis. Moreover, we reveal a link between IL-17A and ER stress through aP2 in macrophages and small inhibitors of aP2 significantly reduced macrophage apoptosis and atherogenesis in ApoE-KO mice. Altogether, our study provides additional evidence and mechanism for a pro-atherogenic role of IL-17A in atherosclerosis.
Increasing data have demonstrated that elevated ER stress in macrophages accelerates the development of early and advanced atherosclerotic lesions. Atherosclerotic plaques, particularly advanced lesions, contain a large amount of toxic lipids (such as saturated fatty acids or free cholesterol) and pro-inflammatory cytokines (tumor necrosis factor [TNF-], interferon IFN-, IL-6, IL-12), which provide a pathophysiological environment. Toxic lipid-induced ER stress in macrophages contributes to cell apoptosis, inflammation in plaque and progression of atherosclerosis. 33, 35, 38, 39 However, few studies have investigated the role of cytokines in inducing ER stress. TNF-induced the UPR in murine fibrosarcoma L929 cells, and lipopolysaccharide (LPS) with IFN-activated ER stress in the macrophage RAW264.7 cell line. 53,54 IL-17A is highly expressed in atherosclerotic lesions, particularly in advanced plaque, in mice and humans and contributes to the development of atherosclerosis. 15 IL-17A can stimulate macrophages to produce a high level of TNF-. 20 We noted that IL-17A-induced ER stress response occurred within 1 to 3 h after IL-17A stimulation (Figure 2 ), and levels of pro-inflammatory molecules, such as TNF-were significantly increased 12 h after IL-17A treatment (Supp. Fig IV) . Thus, TNF-may not be involved in the early activation of IL-17A-induced ER signals. However, increased TNF-level may exacerbate the IL-17A-induced ER stress response. In addition, IL-17A induced ER stress in cultured human and murine-derived macrophages in media containing 10% serum without exogenous toxic lipids ( Figure  2 ). Thus, IL-17A may induce ER stress directly or indirectly by up-regulating TNF-in macrophages independent of toxic lipid levels.
Previous research has shown the lipid chaperone aP2 as a central modulator of lipid-induced ER stress responses. 39 Toxic lipid up-regulate aP2 expression, which promotes the production of phospholipids rich in monounsaturated fatty acids and bioactive lipids that render macrophages resistant to lipid-induced ER stress. Here we demonstrated that aP2 is also a linker of IL-17A-activated ER stress responses in macrophages. aP2 is highly up-regulated with oxidized low-density lipoprotein stimulation in macrophages 51 and Toll-like receptor (TLR) activation by LPS Thus, the pathways may have coevolved common strategies to respond to specific insults. Here, we demonstrated that IL-17A greatly up-regulates the expression of lipid chaperone aP2 mainly by NF-B and ERK, p38 MAPK pathways. This action of IL-17A on aP2 is independent of lipid supplementation in cultured macrophages and alteration of lipid metabolism in hyperlipidemic mice. Furthermore, blocking aP2 markedly mitigated IL-17A-induced ER stress activation and rescued IL-17A-induced atherogenesis. The data establish a previously unrecognized link between IL-17A and ER stress through the cytosolic lipid chaperone aP2 in macrophages.
IL-17A-elevated ER stress in macrophages is required for its promotion of ER stress-associated macrophage apoptosis and atherosclerotic lesions. Several experimental findings have supported CHOP as a transcriptional target for three UPR signal branches and playing an important role in ER stress-associated macrophage apoptosis, particularly in advanced atherosclerotic lesions. In addition in certain cell types, species and conditions, such as murine macrophages, ER stress-mediated apoptosis involves caspase 12 activation. 36, 37 Here we found that IL-17A stimulation markedly elevated CHOP expression but had no obvious impact on caspase 12 activation in vitro and in vivo. More importantly, treatment with the ER chemical chaperone PBA and aP2 inhibitor could alleviate IL-17A-induced ER stress and decrease CHOP expression and the number of apoptotic macrophages in lesions; it could reverse the IL-17A-aggravated atherosclerosis in ApoE-/-mice ( Figure 3, 5) . So we demonstrated that IL-17A-induced ER stress leads to macrophage apoptosis mainly via the CHOP. These data suggest that therapeutic applications targeting ER stress responses may be effective for dyslipidemia and inflammation-promoted atherosclerosis.
We propose that the binding of IL-17A to IL-17A receptor (IL-17RA) in macrophages activates NF-B and MAPK (ERK, p38 and JNK) signal pathways. Activation of the NF-B and p38, ERK pathway is responsible for the up-regulation of the lipid chaperone aP2, which mediates the activation of the ER stress response (elevated expression of p-eIF2 and XBP1s) in macrophages. Chronic ER stress leads to high expression of CHOP, whereby IL-17A induces macrophage apoptosis and then aggravates atherosclerosis. In addition, ER stress may directly influence the development of atherosclerosis (Figure 7) . These findings illustrate a crucial mechanism of how IL-17A may affect macrophage ER stress and exacerbate the development of atherosclerosis. Figure 7 ). Thes Figure 7 ). T Figure 7 ). These Figure 7 ). These ER stress and exa ER stress and ex 
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Novelty and Significance
What Is Known?
Prolonged ER stress induced by high levels of intracellular cholesterol and saturated fatty acids in macrophage triggers apoptosis and accelerates the progression of atherosclerotic plaque. The fatty acid-binding protein-4 (FABP-4) (aP2) is a central modulator of lipid-induced ER stress responses. The proinflammtory cytokine IL-17A, an -Th17 T-cells has been shown to be involved in atherogenesis, but the underlying mechanisms remain unclear.
What New Information Does This Article Contribute?
IL-17A increases the production of FABP-4 (aP2) in macrophage via NF-B and MAPK-regulated signal transduction pathways.
The increase in aP2 is required for IL-17A-induced ER stress, macrophage apoptosis, and acceleration of atherogenesis .
Several studies, including our previous work, suggest that IL-17A is pro-atherogenic. Nevertheless, the mechanism by which IL-17A accelerates atherogenesis remains poorly understood. It has been shown that the cytosolic lipid chaperone aP2 is a central modulator of lipid-induced ER stress responses. In this study, we found that IL-17A induces ER stress in macrophages by up-regulating aP2. Inhibition of aP2 reverted IL-17A-induced ER stress, apoptosis of macrophages and atherosclerosis. These findings reveal a previously unrecognized link between IL-17A and ER stress through aP2 in macrophages and provide a new insight in understanding the role of IL-17A in atherosclerosis. In addition, because aP2 regulates lipid metabolism and signaling, it links inflammation to metabolism. Inhibition of aP2 could provide a new approach for inhibiting atherosclerosis-and related inflammatory diseases. After Online First publication, apparent duplication of panels eIF2a in Figure 2B and 2D, XBP1s in Figure 2D and 3A, and caspase 3 in Figure 4A and 4B was discovered. After being informed by the Editors of these errors, the authors immediately provided the original blots for these figure panels to the Editors. On request of the Editors, the Academic Committee of Shandong University School of Medicine conducted an institutional investigation into apparent duplication of at least 3 figure panels. The investigation confirmed these errors. According to the committee, the authors were able to provide new original blots for these panels that supported their conclusions and attribute these errors to careless management of data. In addition, the original blots of p-eIF2a in Figure 2C and p-PERK in Figure 2D provided to the committee were similar but not identical to the corresponding figures in the article. As reported to the journal by the committee, the authors could only provide blots with a similar trend for CHOP in Figure 4B because the original blots were missing.
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